A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer
Background. Overexpression of Her2neu occurs in 15–20% of patients with gastric cancer and correlates with an unfavorable prognosis. Case report. We report a case of pathological complete regression of resectable gastric cancer with Her2/neu overexpression. The patient received combined modality tre...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2024-03-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/2970 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850041192196079616 |
|---|---|
| author | A. V. Avgustinovich S. G. Afanasyev L. V. Spirina E. V. Kaygorodova R. V. Ermolenko E. N. Samtsov I. G. Frolova O. V. Cheremisina |
| author_facet | A. V. Avgustinovich S. G. Afanasyev L. V. Spirina E. V. Kaygorodova R. V. Ermolenko E. N. Samtsov I. G. Frolova O. V. Cheremisina |
| author_sort | A. V. Avgustinovich |
| collection | DOAJ |
| description | Background. Overexpression of Her2neu occurs in 15–20% of patients with gastric cancer and correlates with an unfavorable prognosis. Case report. We report a case of pathological complete regression of resectable gastric cancer with Her2/neu overexpression. The patient received combined modality treatment including 8 cycles of neoadjuvant chemotherapy with mFLOT + trastuzumab followed by R0 resection. The addition of targeted therapy did not have a negative impact on the perioperative period. Histolohical examination of the surgical specimen revealed pathological complete response (Mandart TGR1). Currently, the patient has been followed-up for 27 months without signs of disease relapse. Conclusion. Total neoadjuvant chemotherapy with mFLОТ+ trastuzumab for operable gastric cancer with Her2/neu overexpression allows us to hope for improved long-term treatment outcomes. |
| format | Article |
| id | doaj-art-95ef8d2d9eef47ee99e031846ff9b874 |
| institution | DOAJ |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| publishDate | 2024-03-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj-art-95ef8d2d9eef47ee99e031846ff9b8742025-08-20T02:55:49ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682024-03-0123117017710.21294/1814-4861-2024-23-1-170-1771210A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancerA. V. Avgustinovich0S. G. Afanasyev1L. V. Spirina2E. V. Kaygorodova3R. V. Ermolenko4E. N. Samtsov5I. G. Frolova6O. V. Cheremisina7Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University of the Ministry of Health of RussiaCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University of the Ministry of Health of RussiaCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesBackground. Overexpression of Her2neu occurs in 15–20% of patients with gastric cancer and correlates with an unfavorable prognosis. Case report. We report a case of pathological complete regression of resectable gastric cancer with Her2/neu overexpression. The patient received combined modality treatment including 8 cycles of neoadjuvant chemotherapy with mFLOT + trastuzumab followed by R0 resection. The addition of targeted therapy did not have a negative impact on the perioperative period. Histolohical examination of the surgical specimen revealed pathological complete response (Mandart TGR1). Currently, the patient has been followed-up for 27 months without signs of disease relapse. Conclusion. Total neoadjuvant chemotherapy with mFLОТ+ trastuzumab for operable gastric cancer with Her2/neu overexpression allows us to hope for improved long-term treatment outcomes.https://www.siboncoj.ru/jour/article/view/2970gastric cancerher2/neu overexpressioncombined modality treatmentneoadjuvant therapycomplete tumor regression |
| spellingShingle | A. V. Avgustinovich S. G. Afanasyev L. V. Spirina E. V. Kaygorodova R. V. Ermolenko E. N. Samtsov I. G. Frolova O. V. Cheremisina A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer Сибирский онкологический журнал gastric cancer her2/neu overexpression combined modality treatment neoadjuvant therapy complete tumor regression |
| title | A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer |
| title_full | A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer |
| title_fullStr | A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer |
| title_full_unstemmed | A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer |
| title_short | A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer |
| title_sort | case of pathological complete regression in combined modality treatment of resectable her2 neu positive gastric cancer |
| topic | gastric cancer her2/neu overexpression combined modality treatment neoadjuvant therapy complete tumor regression |
| url | https://www.siboncoj.ru/jour/article/view/2970 |
| work_keys_str_mv | AT avavgustinovich acaseofpathologicalcompleteregressionincombinedmodalitytreatmentofresectableher2neupositivegastriccancer AT sgafanasyev acaseofpathologicalcompleteregressionincombinedmodalitytreatmentofresectableher2neupositivegastriccancer AT lvspirina acaseofpathologicalcompleteregressionincombinedmodalitytreatmentofresectableher2neupositivegastriccancer AT evkaygorodova acaseofpathologicalcompleteregressionincombinedmodalitytreatmentofresectableher2neupositivegastriccancer AT rvermolenko acaseofpathologicalcompleteregressionincombinedmodalitytreatmentofresectableher2neupositivegastriccancer AT ensamtsov acaseofpathologicalcompleteregressionincombinedmodalitytreatmentofresectableher2neupositivegastriccancer AT igfrolova acaseofpathologicalcompleteregressionincombinedmodalitytreatmentofresectableher2neupositivegastriccancer AT ovcheremisina acaseofpathologicalcompleteregressionincombinedmodalitytreatmentofresectableher2neupositivegastriccancer AT avavgustinovich caseofpathologicalcompleteregressionincombinedmodalitytreatmentofresectableher2neupositivegastriccancer AT sgafanasyev caseofpathologicalcompleteregressionincombinedmodalitytreatmentofresectableher2neupositivegastriccancer AT lvspirina caseofpathologicalcompleteregressionincombinedmodalitytreatmentofresectableher2neupositivegastriccancer AT evkaygorodova caseofpathologicalcompleteregressionincombinedmodalitytreatmentofresectableher2neupositivegastriccancer AT rvermolenko caseofpathologicalcompleteregressionincombinedmodalitytreatmentofresectableher2neupositivegastriccancer AT ensamtsov caseofpathologicalcompleteregressionincombinedmodalitytreatmentofresectableher2neupositivegastriccancer AT igfrolova caseofpathologicalcompleteregressionincombinedmodalitytreatmentofresectableher2neupositivegastriccancer AT ovcheremisina caseofpathologicalcompleteregressionincombinedmodalitytreatmentofresectableher2neupositivegastriccancer |